152 related articles for article (PubMed ID: 38578002)
41. Cost per cumulative clinical benefit of biologic therapies for patients with plaque psoriasis: a systematic review.
Blauvelt A; Burge R; Malatestinic W; Brnabic A; Guo J; Janardhanan M; Zhu B
J Manag Care Spec Pharm; 2021 Jan; 27(1):84-94. PubMed ID: 33377444
[No Abstract] [Full Text] [Related]
42. Comparative effectiveness of biologics in clinical practice: week 12 primary outcomes from an international observational psoriasis study of health outcomes (PSoHO).
Pinter A; Puig L; Schäkel K; Reich A; Zaheri S; Costanzo A; Tsai TF; Smith SD; Lynde C; Brnabic A; Reed C; Hill J; Schuster C; Riedl E; Paul C
J Eur Acad Dermatol Venereol; 2022 Nov; 36(11):2087-2100. PubMed ID: 35766124
[TBL] [Abstract][Full Text] [Related]
43. Psoriasis treat to target: defining outcomes in psoriasis using data from a real-world, population-based cohort study (the British Association of Dermatologists Biologics and Immunomodulators Register, BADBIR).
Mahil SK; Wilson N; Dand N; Reynolds NJ; Griffiths CEM; Emsley R; Marsden A; Evans I; Warren RB; Stocken D; Barker JN; Burden AD; Smith CH;
Br J Dermatol; 2020 May; 182(5):1158-1166. PubMed ID: 31286471
[TBL] [Abstract][Full Text] [Related]
44. Change in body weight and body mass index in psoriasis patients receiving biologics: A systematic review and network meta-analysis.
Wu MY; Yu CL; Yang SJ; Chi CC
J Am Acad Dermatol; 2020 Jan; 82(1):101-109. PubMed ID: 31400455
[TBL] [Abstract][Full Text] [Related]
45. Systemic pharmacological treatments for chronic plaque psoriasis: a network meta-analysis.
Sbidian E; Chaimani A; Garcia-Doval I; Doney L; Dressler C; Hua C; Hughes C; Naldi L; Afach S; Le Cleach L
Cochrane Database Syst Rev; 2021 Apr; 4(4):CD011535. PubMed ID: 33871055
[TBL] [Abstract][Full Text] [Related]
46. Durable dermatology life quality index improvements in patients on biologics associated with psoriasis areas and severity index: a longitudinal study.
Chaptini C; Quinn S; Marshman G
Australas J Dermatol; 2016 Aug; 57(3):e72-5. PubMed ID: 26010650
[TBL] [Abstract][Full Text] [Related]
47. Superiority in Quality of Life Improvement of Biologics over Conventional Systemic Drugs in a Swiss Real-Life Psoriasis Registry.
Jungo P; Maul JT; Djamei V; von Felten S; Kolios AGA; Czernielewsk J; Yawalkar N; Odermatt O; Laffitte E; Anliker M; Streit M; Augustin M; Conrad C; Hafner J; Boehncke WH; Gilliet M; Itin P; French LE; Navarini AA; Häusermann P
Dermatology; 2016; 232(6):655-663. PubMed ID: 28103601
[TBL] [Abstract][Full Text] [Related]
48. Dose reduction of the new generation biologics (IL-17 and IL-23 inhibitors) in psoriasis: study protocol for an international, pragmatic, multicenter, randomized, controlled, non-inferiority study-the BeNeBio study.
van der Schoot LS; van den Reek JMPA; Grine L; Schots L; Kievit W; Lambert JLW; de Jong EMGJ
Trials; 2021 Oct; 22(1):707. PubMed ID: 34656148
[TBL] [Abstract][Full Text] [Related]
49. Comparison of cumulative clinical benefits of biologics for the treatment of psoriasis over 16 weeks: Results from a network meta-analysis.
Warren RB; Gooderham M; Burge R; Zhu B; Amato D; Liu KH; Shrom D; Guo J; Brnabic A; Blauvelt A
J Am Acad Dermatol; 2020 May; 82(5):1138-1149. PubMed ID: 31884091
[TBL] [Abstract][Full Text] [Related]
50. Impact of previous biologic use on the efficacy and safety of brodalumab and ustekinumab in patients with moderate-to-severe plaque psoriasis: integrated analysis of the randomized controlled trials AMAGINE-2 and AMAGINE-3.
Papp KA; Gordon KB; Langley RG; Lebwohl MG; Gottlieb AB; Rastogi S; Pillai R; Israel RJ
Br J Dermatol; 2018 Aug; 179(2):320-328. PubMed ID: 29488226
[TBL] [Abstract][Full Text] [Related]
51. A multinational, prospective, observational study to estimate complete skin clearance in patients with moderate-to-severe plaque PSOriasis treated with BIOlogics in a REAL world setting (PSO-BIO-REAL).
Seneschal J; Lacour JP; Bewley A; Faurby M; Paul C; Pellacani G; De Simone C; Horne L; Sohrt A; Augustin M; Hammond E; Reich K
J Eur Acad Dermatol Venereol; 2020 Nov; 34(11):2566-2573. PubMed ID: 32364296
[TBL] [Abstract][Full Text] [Related]
52. Psoriasis mutations disrupt CARD14 autoinhibition promoting BCL10-MALT1-dependent NF-κB activation.
Howes A; O'Sullivan PA; Breyer F; Ghose A; Cao L; Krappmann D; Bowcock AM; Ley SC
Biochem J; 2016 Jun; 473(12):1759-68. PubMed ID: 27071417
[TBL] [Abstract][Full Text] [Related]
53. Utility of the Dermatology Life Quality Index at initiation or switching of biologics in real-life Japanese patients with plaque psoriasis: Results from the ProLOGUE study.
Imafuku S; Kanai Y; Murotani K; Nomura T; Ito K; Ohata C; Yamazaki F; Miyagi T; Takahashi H; Okubo Y; Saeki H; Honma M; Tada Y; Mabuchi T; Higashiyama M; Kobayashi S; Hashimoto Y; Seishima M; Kakuma T
J Dermatol Sci; 2021 Mar; 101(3):185-193. PubMed ID: 33495058
[TBL] [Abstract][Full Text] [Related]
54. Risankizumab for the treatment of moderate-to-severe psoriasis: A multicenter, retrospective, 1 year real-life study.
Caldarola G; Zangrilli A; Bernardini N; Bavetta M; De Simone C; Graceffa D; Bonifati C; Faleri S; Giordano D; Mariani M; Micheli A; Moretta G; Pagnanelli G; Panasiti V; Provini A; Richetta A; Peris K; Bianchi L
Dermatol Ther; 2022 Jun; 35(6):e15489. PubMed ID: 35385202
[TBL] [Abstract][Full Text] [Related]
55. Systemic pharmacological treatments for chronic plaque psoriasis: a network meta-analysis.
Sbidian E; Chaimani A; Garcia-Doval I; Doney L; Dressler C; Hua C; Hughes C; Naldi L; Afach S; Le Cleach L
Cochrane Database Syst Rev; 2022 May; 5(5):CD011535. PubMed ID: 35603936
[TBL] [Abstract][Full Text] [Related]
56. Ustekinumab in psoriasis: Five-year real life experience from a single tertiary centre.
Acer E; İğrek A; Erdoğan HK; Saracoğlu ZN
Dermatol Ther; 2020 Mar; 33(2):e13224. PubMed ID: 31917491
[TBL] [Abstract][Full Text] [Related]
57. Management of gastric mucosa-associated lymphoid tissue lymphoma in patients with extra copies of the
Iwamuro M; Takenaka R; Nakagawa M; Moritou Y; Saito S; Hori S; Inaba T; Kawai Y; Toyokawa T; Tanaka T; Yoshino T; Okada H
World J Gastroenterol; 2017 Sep; 23(33):6155-6163. PubMed ID: 28970731
[TBL] [Abstract][Full Text] [Related]
58. Onset of Action of Biologics in Patients With Moderate-to-Severe Psoriasis.
Papp KA; Lebwohl MG
J Drugs Dermatol; 2018 Mar; 17(3):247-250. PubMed ID: 29537442
[TBL] [Abstract][Full Text] [Related]
59. Outcomes in Ixekizumab Patients Following Exposure to Secukinumab and Other Biologics in the CorEvitas Psoriasis Registry.
Lockshin B; Harrison RW; McLean RR; Crabtree MM; Konicek BW; Zhu B; Malatestinic WN; Atiya B; Murage MJ; Burge RT
Dermatol Ther (Heidelb); 2022 Dec; 12(12):2797-2815. PubMed ID: 36331713
[TBL] [Abstract][Full Text] [Related]
60. Mucosa-associated lymphoid tissue lymphoma translocation protein 1 exaggerates multiple organ injury, inflammation, and immune cell imbalance by activating the NF-κB pathway in sepsis.
Wang Y; Liu Z; Zhang M; Yu B; Ai F
Front Microbiol; 2023; 14():1117285. PubMed ID: 36960276
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
